

Redox regulation of metabolism in asthma

Citation for published version (APA):

van de Wetering, C. (2021). *Redox regulation of metabolism in asthma: new insights into the roles of Glutathione-S-transferase P*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20210510cw>

Document status and date:
Published: 01/01/2021

DOI:
[10.26481/dis.20210510cw](https://doi.org/10.26481/dis.20210510cw)

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Impact

Background

Asthma is defined as a heterogeneous pulmonary disease, characterized by chronic inflammation, which affects more than 300 million people worldwide (1). The pathophysiology of asthma consists of structural changes in the airways that may induce symptoms including chest tightness, frequent coughs and wheezes as well as airway obstruction together with variable airflow limitation (2). These typical asthma symptoms vary over time and intensity and can affect daily life activities and reduce the quality of life in asthmatic patients. Asthma is generally not seen as a disease with high mortality, but according to the WHO, at least 350,000 deaths are attributed to asthma annually (3, 4). Current available therapeutics target symptoms but do not cure disease, and unfortunately, a significant patient population remains for whom these treatments are not effective. The fundamental causes of asthma are still not fully understood but are likely a combination of genetic profile and external factors. Moreover, it has to be taken into account that every individual is different in terms of their physiological and genetic profile. To better categorize asthmatic patients, several subtypes of asthma exist called endotypes and phenotypes, although it is hard to define patients into endotypes and phenotypes as overlap exists (5). Especially patients with severe asthma do not respond to current treatment, have uncontrolled disease and are hard to define into subgroups. To obtain better therapeutics, it is critical to understand the fundamental causes and the underlying (molecular) mechanisms of asthma pathophysiology. This way, asthmatics can be better classified in order to personalize treatment.

Research and relevance

Abnormal cellular metabolism is implicated in the pathogenesis of several diseases, including diabetes, cancer as well as multiple chronic lung diseases (6). Metabolomic approaches on blood, and urine revealed that fatty acid and lipid metabolism were affected in asthmatics (7-9), but the metabolic alterations in lung tissues and specifically in epithelial cells, that drive the inflammatory response in asthmatics, remained largely unexplored. The first main objective of this thesis was to examine if alterations in cellular metabolism contribute to asthma pathology and secondly, whether metabolic changes are regulated by changes in the oxidative environment, notably by redox perturbations. The main results of

this thesis demonstrate that increases in the glycolysis pathway, which is a process that involves the breakdown of glucose to extract energy for cell metabolism, contribute to pathophysiological manifestations underlying asthma including increased lung inflammation and worsened lung function. Moreover, our results demonstrate that a pro-inflammatory mediator, Interleukin-1 β (IL-1 β), is an important signal that induces these increases in glycolysis during asthma which corresponded with increased levels of lactate, which is an indicative of disturbed cell metabolism and worsened disease. Interestingly, our data displayed that IL-1 β was associated with neutrophilic asthma (has been linked to more severe disease), rather than eosinophilic asthma, which is in line with published results showing that IL-1 β is an important neutrophil activator (10). Additionally, IL-1 β increases the expression of the epithelial cell-derived cytokine TSLP in epithelial cells, which is linked to steroid resistance and severe airway inflammation. This thesis moreover highlights the importance of the glycolysis pathway during asthma by showing that the key, rate-limiting, enzyme of the glycolysis pathway, called Pyruvate Kinase M2, contributes to asthma pathology. Our second objective was focused on Glutathione-S-transferase Pi (GSTP), a redox-based enzyme that is highly expressed in the lung and in epithelial cells, which also functions in cellular detoxification by neutralizing toxic and carcinogenic compounds in our body. GSTP catalyzes an oxidative process that changes the function of proteins, thereby affecting processes including metabolic pathways (11). Interestingly, our results displayed that GSTP worsens asthma by changing cellular metabolism, notably by affecting the glycolysis enzyme Pyruvate Kinase M2.

As mentioned, asthmatics with severe disease often do not respond to current treatments. Severe asthma is associated with increased mortality and hospitalization, reduced quality of life and increased health care costs, and accounts for approximately 5-10% of all confirmed asthma cases in developed countries (12). As this thesis highlights the importance of cellular metabolism in asthma, monitoring changes in cellular metabolism in patients (with severe disease) in the clinic could be useful to gain better insights into the underlying mechanisms and may lead to new and better therapeutics. Results in this thesis showed that the pro-inflammatory mediator IL-1 β drives increases in glycolysis in association with increased lactate levels in sputum of asthmatic patients. Therefore, lactate

as well as IL-1 β levels in sputum as well as in blood could be non-invasive, quick and reliable biomarkers to identify patients with altered cell metabolism (glycolysis) and improve diagnostics and characterization of patients into endotypes and phenotypes.

Our results moreover highlight the importance of the key glycolysis enzyme Pyruvate Kinase M2 in asthma pathology, and showed that its function can be altered by the redox-based enzyme GSTP. Inhibition of GSTP moreover displayed reduced lactate levels and inflammation from epithelial cells. GSTP and PKM2 are also shown to be present in extracellular fluids including bronchoalveolar lavage and sputum. Therefore, Pyruvate Kinase M2 and/or GSTP could be potential targets for the development of anti-inflammatory therapies and inhibition of glycolysis for the treatment of asthmatics with high IL-1 β levels and increased glycolysis.

Target groups and activity

Screening for alterations in cellular metabolism will not only be beneficial for asthmatics. It has for instance been shown that inhibition of glycolysis may have therapeutic benefit in lung fibrosis in animal models (13). Inhibition of glycolysis has also been tested in other metabolic disorders such as cancer and inflammatory diseases, and increased IL-1 β levels have been associated with more inflammation in patients with severe persistent allergic rhinitis as well as in COPD patients (14, 15). Moreover, it was found that patients with COVID-19 displayed higher IL-1 β levels in plasma than healthy subjects (16). Moreover, lung immune cells (that also play important roles in asthma) from COVID-19 patients displayed altered metabolism, increased levels of Pyruvate Kinase M2, as well as lactate levels. It is thought that these increases in cellular metabolism contribute to disease pathology, and severity of disease (e.g. more symptoms and hospitalization) and underline the importance of this research.

While there is debate whether asthma cases are increasing or not, it is worrisome that asthma is often underdiagnosed as well as undertreated. The development of asthma is complicated since it is often related to other factors including immunological factors, age, gender and obesity. Obesity-related asthma is linked to more severe disease and up to 30% of obese asthma patients do not respond to steroids (17). According to the CDC, the

prevalence of obesity is increasing and is currently approximately observed in 42,4% of the global population. Aging is another factor that is increasing, and asthma in elderly patients presents itself differently, with higher mortality rates. Therefore, deaths or incidents due to obesity or aging are not always directly linked to asthma. IL-1 β has already emerged as a biomarker in obesity (18), and it is suggested that IL-1 β participates in fundamental inflammatory processes that increase during the aging process (19).

It is important that target groups will be informed about research findings to incorporate potential novel and improved strategies in the clinic. Results from this thesis will be published in scientific journals which are available to a broad spectrum of people. However, patients without a background in science or healthcare rarely have access to or read these articles and they should be informed as well. The connection and communication between scientists and other healthcare professionals including medical doctors and nurses is essential. Moreover, patients including their families, friends and/or caretakers should be informed about novel research in an understandable way via healthcare professionals, health magazines or via (social) media sources. Important is that people with scientific backgrounds communicate the findings on these platforms, as data often is misunderstood or miscommunicated via the media. The Longdagen ('Days of the Lungs') is a conference held in the Netherlands where scientists, doctors, nurses and patients come together and discuss the latest findings regarding lung diseases. More gatherings like these should be organized and advertised as well as routine social meetings with patients, families and/or caretakers and pulmonary professionals including doctors and scientists would be essential to share most valuable information regarding better treatment strategies. Social media platforms such as twitter, linkedIN, and TED talks nowadays also share research outcomes, and improve the dissemination of research. Research funders can be of help to research organizations to develop knowledge uptake skills and promote research communication (20).

REFERENCES

1. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* (London, England). 2017;390(10100):1211-59.
2. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. *The European respiratory journal*. 2015;46(3):622-39.
3. Croisant S. Epidemiology of asthma: prevalence and burden of disease. *Adv Exp Med Biol*. 2014;795:17-29.
4. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract*. 2017;3:1.
5. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. *Clin Rev Allergy Immunol*. 2019;56(2):219-33.
6. Michaeloudes C, Bhavsar PK, Mumby S, Xu B, Hui CKM, Chung KF, et al. Role of Metabolic Reprogramming in Pulmonary Innate Immunity and Its Impact on Lung Diseases. *J Innate Immun*. 2020;12(1):31-46.
7. McGeachie MJ, Dahlin A, Qiu W, Croteau-Chonka DC, Savage J, Wu AC, et al. The metabolomics of asthma control: a promising link between genetics and disease. *Immun Inflamm Dis*. 2015;3(3):224-38.
8. Reinke SN, Gallart-Ayala H, Gomez C, Checa A, Fauland A, Naz S, et al. Metabolomics analysis identifies different metabolotypes of asthma severity. *The European respiratory journal*. 2017;49(3).
9. Carraro S, Bozzetto S, Giordano G, El Mazloum D, Stocchero M, Pirillo P, et al. Wheezing preschool children with early-onset asthma reveal a specific metabolomic profile. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2018;29(4):375-82.
10. Prince LR, Allen L, Jones EC, Hellewell PG, Dower SK, Whyte MK, et al. The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. *The American journal of pathology*. 2004;165(5):1819-26.
11. Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD. Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress. *The Journal of biological chemistry*. 2009;284(1):436-45.
12. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2019. <https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf>.
13. Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, et al. Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. *American journal of respiratory and critical care medicine*. 2015;192(12):1462-74.
14. Han MW, Kim SH, Oh I, Kim YH, Lee J. Serum IL-1beta can be a biomarker in children with severe persistent allergic rhinitis. *Allergy Asthma Clin Immunol*. 2019;15:58.
15. Yi G, Liang M, Li M, Fang X, Liu J, Lai Y, et al. A large lung gene expression study identifying IL1B as a novel player in airway inflammation in COPD airway epithelial cells. *Inflamm Res*. 2018;67(6):539-51.
16. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. *American journal of respiratory and critical care medicine*. 2020;202(6):812-21.
17. Peters U, Dixon AE, Forno E. Obesity and asthma. *The Journal of allergy and clinical immunology*. 2018;141(4):1169-79.
18. Enquobahrie DA, Rice K, Williams OD, Williams MA, Gross MD, Lewis CE, et al. IL1B genetic variation and plasma C-reactive protein level among young adults: the CARDIA study. *Atherosclerosis*. 2009;202(2):513-20.
19. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. *Am J Clin Nutr*. 2006;83(2):447S-55S.
20. Aberle MR, Burkhart RA, Tiriach H, Olde Damink SWM, Dejong CHC, Tuveson DA, et al. Patient-derived organoid models help define personalized management of gastrointestinal cancer. *Br J Surg*. 2018;105(2):e48-e60.